

Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently Amended) ~~An expression enhancer for protein synthesis inhibitory genes, said expression enhancer comprising~~ A pharmaceutical composition, consisting of IFN- α 2 subtype of SEQ ID NO:1 and IFN- α 8 subtype of SEQ ID NO:2 of human IFN- α as active ingredients and a pharmaceutically acceptable carrier, wherein said IFN- α 2 subtype present is in an activity ratio at least 1:0.25 but below 1:1.5 to IFN- α 8 subtype, or in a weight ratio of 1:0.05 to 1:0.5 to IFN- α 8 subtype.

Claims 2-8. (Cancelled)

9. (Currently Amended) ~~The expression enhancer~~ pharmaceutical composition according to claim 1 wherein the IFN- α 2 and IFN- α 8 subtypes have a water-soluble macromolecule covalently coupled to the peptide chains of the subtypes.

Claims 10-18. (Cancelled)